EZH2 and Miyoshi myopathy: Moreover, treatment of MM cells with EZH2 inhibitors, such as the S-adenosyl-homocysteine hydrolase inhibitor 3-Deazaneplanocin (DZNep), GSK343 or EPZ005687 [25, 26], reduced H3K27me3 levels and triggered miR-29b upregulation in MM cell lines (Figure 2C).